Business Description
Surgical Science Sweden AB
ISIN : SE0014428512
Total Employee Number:
309Description
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 311.15 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-EBITDA | 0.03 | |||||
Interest Coverage | 54.65 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 3.12 | |||||
Beneish M-Score | -2.54 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.3 | |||||
3-Year EBITDA Growth Rate | -10.2 | |||||
3-Year EPS without NRI Growth Rate | -29.2 | |||||
3-Year FCF Growth Rate | -31.6 | |||||
3-Year Book Growth Rate | 0.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 38.75 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.93 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 89.89 | |||||
9-Day RSI | 91.63 | |||||
14-Day RSI | 91.96 | |||||
3-1 Month Momentum % | 40.85 | |||||
6-1 Month Momentum % | 10.19 | |||||
12-1 Month Momentum % | -73.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.44 | |||||
Quick Ratio | 3.66 | |||||
Cash Ratio | 2.5 | |||||
Days Inventory | 219.25 | |||||
Days Sales Outstanding | 49.58 | |||||
Days Payable | 51.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 0.88 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 65.5 | |||||
Operating Margin % | 6.95 | |||||
Net Margin % | 5.34 | |||||
EBITDA Margin % | 6.95 | |||||
FCF Margin % | 9.64 | |||||
OCF Margin % | 15.43 | |||||
ROE % | 1.2 | |||||
ROA % | 1.1 | |||||
ROIC % | 1.14 | |||||
3-Year ROIIC % | 68.48 | |||||
ROC (Joel Greenblatt) % | 36.86 | |||||
ROCE % | 1.51 | |||||
Years of Profitability over Past 10-Year | 8 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 29.9 | |||||
Forward PE Ratio | 17.54 | |||||
PE Ratio without NRI | 29.9 | |||||
Shiller PE Ratio | 19.39 | |||||
Price-to-Owner-Earnings | 67.99 | |||||
PEG Ratio | 1.12 | |||||
PS Ratio | 1.61 | |||||
PB Ratio | 0.36 | |||||
Price-to-Tangible-Book | 1.68 | |||||
Price-to-Free-Cash-Flow | 16.82 | |||||
Price-to-Operating-Cash-Flow | 10.48 | |||||
EV-to-EBIT | 13.35 | |||||
EV-to-Forward-EBIT | 6.85 | |||||
EV-to-EBITDA | 13.35 | |||||
EV-to-Forward-EBITDA | 4.32 | |||||
EV-to-Revenue | 0.93 | |||||
EV-to-Forward-Revenue | 0.93 | |||||
EV-to-FCF | 9.7 | |||||
Price-to-GF-Value | 0.28 | |||||
Price-to-Projected-FCF | 0.33 | |||||
Price-to-DCF (Earnings Based) | 0.96 | |||||
Price-to-DCF (FCF Based) | 0.62 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.55 | |||||
Price-to-Graham-Number | 1.5 | |||||
| Price-to-Net-Current-Asset-Value | 1.97 | |||||
| Price-to-Net-Cash | 5.63 | |||||
Earnings Yield (Greenblatt) % | 7.49 | |||||
FCF Yield % | 5.95 | |||||
Forward Rate of Return (Yacktman) % | 17.61 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:SUSRF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Surgical Science Sweden AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 104.237 | ||
| EPS (TTM) ($) | 0.112 | ||
| Beta | 1.1196 | ||
| 3-Year Sharpe Ratio | -0.55 | ||
| 3-Year Sortino Ratio | -0.66 | ||
| Volatility % | 81.35 | ||
| 14-Day RSI | 91.96 | ||
| 14-Day ATR ($) | 0.015229 | ||
| 20-Day SMA ($) | 4 | ||
| 12-1 Month Momentum % | -73.51 | ||
| 52-Week Range ($) | 2.84 - 15.471 | ||
| Shares Outstanding (Mil) | 51.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Surgical Science Sweden AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Surgical Science Sweden AB Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 | In 138 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 138 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-19 | In 53 days | ||
| Second quarter earnings results for 2026 | 2026-08-19 | In 53 days | ||
| General meeting for 2026 | 2026-05-21 15:00 | 4.09 (+3.54%) | ||
| First quarter earnings conference call for 2026 | 2026-05-20 11:00 | 2.84 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-20 07:30 | 2.84 (+0.00%) | ||
| Annual report for 2025 | 2026-04-15 | 2.84 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-19 11:00 | 2.84 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-19 07:30 | 2.84 (+0.00%) |
Show
Entries
Surgical Science Sweden AB Frequently Asked Questions
What is Surgical Science Sweden AB(SUSRF)'s stock price today?
The current price of SUSRF is $4.00. The 52 week high of SUSRF is $15.47 and 52 week low is $2.84.
When is next earnings date of Surgical Science Sweden AB(SUSRF)?
The next earnings date of Surgical Science Sweden AB(SUSRF) is 2026-08-19.
Does Surgical Science Sweden AB(SUSRF) pay dividends? If so, how much?
Surgical Science Sweden AB(SUSRF) does not pay dividend.
Guru Commentaries on OTCPK:SUSRF
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Surgical Science Sweden AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers